Limits On 'Orphan Drug' Tax Credit Face Pushback In Senate
By Alan K. Ota · March 3, 2022, 3:40 PM EST
A House-passed plan to raise revenue for Democratic priorities by limiting tax breaks for so-called orphan drugs used to treat rare diseases faces Senate hurdles as allies of the pharmaceutical industry...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login
